Tag: venovalve

deep venous

Deep venous valve technologies set to address “large unmet need worldwide”

The pursuit of a cure for deep venous valvular reflux—long considered to be the “holy grail” of deep venous disease—is underway, with new technologies...
venous valve

AVF 2023: Investigators report update on three-year first-in-human results for bioprosthetic...

Researchers in Colombia behind the first-in-human study of a novel bioprosthetic venous valve designed to treat chronic venous insufficiency (CVI) reported three-year results among...
first-in-human

First-in-human patients continue to benefit from VenoValve at average of three...

Positive long-term, three-year observational data from a cohort of patients that participated in the previously concluded VenoValve (Envveno Medical) first-in-human clinical trial were recently...

AVF 2022: VenoValve improvement “maintained” for 2.5 years without adverse events

Envveno Medical announced positive 30-month data from the first-in-human trial of the VenoValve bioprosthetic potential venous valve replacement during the 2022 American Venous Forum...
first-in-human

Envveno Medical reports successful completion of first VenoValve surgery for US...

Envveno Medical, formerly Hancock Jaffe Laboratories, recently announced that the first VenoValve surgery in the company’s SAVVE US pivotal trial for the VenoValve has...

“The future is very bright for venous valve replacement”

The progress of two “promising” new devices in the venous valve replacement space were outlined during a special session at the Society for Vascular...

Hancock Jaffe presents positive two-year VenoValve data at SVS VAM 2021

Hancock Jaffe Laboratories has announced that promising two-year post-VenoValve implantation data are being presented today at the Society for Vascular Surgery’s Vascular Annual Meeting...

FDA grants Breakthrough Device designation status for Hancock Jaffe’s VenoValve

Hancock Jaffe Laboratories today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation status to the VenoValve, the company’s...

First US patent issues on Hancock Jaffe VenoValve

Hancock Jaffe Laboratories has revealed that the United States Patent and Trademark Office (USPTO) has issued the first patent covering the company's VenoValve. The...

Hancock Jaffe receives IDE approval to begin VenoValve US pivotal trial

Hancock Jaffe Laboratories recently announced that the US Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption (IDE) application to begin...

Hancock Jaffe, maker of the VenoValve, completes US$41 million public offering

Hancock Jaffe Laboratories recently announced that it has completed a public offering of its securities, generating approximately US$41.4 million of gross proceeds, prior to...
VenoValve and improving clinical outcomes

Initial results from first-in-man trial of prosthetic VenoValve demonstrate promise

Initial results of an ongoing first-in-man study in Colombia, that saw the implantation of a prosthetic venous valve in 15 patients, have demonstrated an...
VenoValve and improving clinical outcomes

Endpoints for first-in-human VenoValve study announced by Hancock Jaffe

Medical device company Hancock Jaffe has announced the end-points for its upcoming VenoValve first-in-human study in Bogota, Colombia. Endpoints for the study will include...
VenoValve and improving clinical outcomes

Medical research committee gives approval for first-in-man VenoValve study

Hancock Jaffe Laboratories, a company specialising in bioprosthetic medical devices for treating cardiac and vascular diseases, has received approval for the first-in-man testing of...